Vaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $127,308.79 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the transaction, the senior vice president now directly owns 30,826 shares of the company’s stock, valued at approximately $2,354,181.62. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Mikhail Eydelman also recently made the following trade(s):

• On Monday, June 3rd, Mikhail Eydelman sold 1,667 shares of Vaxcyte stock. The shares were sold at an average price of $72.06, for a total transaction of $120,124.02.

Vaxcyte Price Performance

PCVX opened at $76.26 on Friday. The firm has a 50 day moving average price of $70.84 and a 200 day moving average price of $68.34. Vaxcyte, Inc. has a 1 year low of $44.20 and a 1 year high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. As a group, analysts forecast that Vaxcyte, Inc. will post -3.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a research note on Friday, June 28th.

Institutional Trading of Vaxcyte

A number of institutional investors and hedge funds have recently bought and sold shares of PCVX. Parallel Advisors LLC boosted its holdings in Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the period. Fidelis Capital Partners LLC purchased a new position in Vaxcyte in the 1st quarter worth approximately $37,000. Covestor Ltd boosted its holdings in Vaxcyte by 451.7% in the 1st quarter. Covestor Ltd now owns 1,153 shares of the company’s stock worth $79,000 after acquiring an additional 944 shares during the period. Banque Cantonale Vaudoise boosted its holdings in Vaxcyte by 96.7% in the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after acquiring an additional 582 shares during the period. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Vaxcyte in the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.